Protocol Expansion Broadens Phase 3 HERO Trial Eligibility Criteria to Include Children Ages 7+ in the United StatesSAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) ...
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and ...
Clinical Trials Arena on MSN
Aardvark gains IRB approval for ARD-101 trial to treat Prader-Willi syndrome
Aardvark intends to enrol 90 patients across Australia, Canada, South Korea, the UK, and the US.
Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral ...
SAN DIEGO, CA / ACCESS Newswire / September 15, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the $3 ...
Company reaches next clinical trial milestone for the intramuscular treatment of Chronic Lower Back Pain with the first novel allogenic cellular therapy in the United States PHOENIX, Oct. 10, 2023 ...
SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the $3 ...
-Study to Evaluate Usability and Extended Wear for Next-Generation Tubeless Patch Pump SAN DIEGO, CA / ACCESS Newswire / September 15, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or ...
“Securing IRB approval from Hadassah-University Medical Center, a globally respected institution, marks another important step in our journey to address the deep unmet need in Alcohol Use Disorder,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results